Bincy P. Abraham, MD

Fondren Distinguished Professor in Inflammatory Bowel Disease, Department of Medicine
Professor of Clinical Medicine, Academic Institute
Full Clinical Member, Research Institute
Program Director, Gastroenterology Fellowship Program, Lynda K. and David M. Underwood Center for Digestive Disorders
Houston Methodist
Weill Cornell Medical College


Bincy P. Abraham, MD, MS, is an associate professor of clinical medicine in the Academic Division of Gastroenterology and Hepatology at Houston Methodist – Weill Cornell in Houston, Texas.

Dr. Abraham earned her undergraduate degree in bioengineering at Texas A&M University in College Station, and then received her medical degree from the University of Texas Medical Branch (UTMB) in Galveston. She completed her internal medicine internship and residency, as well as a gastroenterology fellowship at UTMB, where she also earned a master’s in clinical investigation and received specialized training in inflammatory bowel disease (IBD). During her training, she completed a National Visiting Fellow IBD Rotation Program through the Crohn’s and Colitis Foundation of America at Cedars-Sinai Medical Center in Los Angeles, California. She is board certified in Internal medicine and Gastroenterology. Dr. Abraham is a member of the American Gastroenterological Association, American College of Gastroenterology, Crohn’s and Colitis Foundation, American Society of Gastrointestinal Endoscopy, and chair of the South Texas Chapter of the Crohn’s and Colitis Foundation Medical Advisory Committee.

Description of Research

Dr. Abraham is a principal investigator and coinvestigator in several key clinical trials. As author or coauthor, Dr. Abraham’s work has been published in peer-reviewed medical journals including Clinical Gastroenterology and Hepatology, American Journal of Gastroenterology, and Inflammatory Bowel Diseases.

Areas Of Expertise

Crohn's disease Pregnancy & inflammatory bowel disease Transition of care in inflammatory bowel disease Ulcerative colitis

Positioning biologics and small molecules in the management of moderate to severe ulcerative colitis
Abraham, B & Glassner, K 2021, , Current opinion in gastroenterology, vol. 37, no. 4, pp. 344-350.

Epithelial Cell Biomarkers Are Predictive of Response to Biologic Agents in Crohn's Disease
Osterman, MT, Vandussen, KL, Gordon, IO, Davis, EM, Li, K, Simpson, K, Ciorba, M, Glover, SC, Abraham, B, Guo, X, Yee, EU, Allard, FD, Perrigoue, JG, Claggett, B, Shen, B, Stappenbeck, TS & Liu, JJ 2021, , Inflammatory bowel diseases, vol. 27, no. 5, pp. 677-685.

Inflammatory Bowel Disease and Atherosclerotic Cardiovascular Disease: JACC Review Topic of the Week
Cainzos-Achirica, M, Glassner, K, Zawahir, HS, Dey, AK, Agrawal, T, Quigley, EMM, Abraham, BP, Acquah, I, Yahya, T, Mehta, NN & Nasir, K 2020, , Journal of the American College of Cardiology, vol. 76, no. 24, pp. 2895-2905.

Mucosal biomarker of innate immune activation predicts response to vedolizumab in crohn s disease
Osterman, MT, Gordon, IO, Davis, EM, Ciorba, M, Glover, SC, Abraham, B, Khan, F, Guo, X, Yee, EU, Allard, FD, Claggett, B, Shen, B & Liu, JJ 2020, , Inflammatory bowel diseases, vol. 26, no. 10, pp. 1554-1561.

The use of combination biological or small molecule therapy in inflammatory bowel disease: A retrospective cohort study
Glassner, K, Oglat, A, Duran, A, Koduru, P, Perry, C, Wilhite, A & Abraham, BP 2020, , Journal of Digestive Diseases, vol. 21, no. 5, pp. 264-271.

Erratum: Antibiotics and probiotics in inflammatory bowel disease: When to use them? (Frontline Gastroenterology (2020) 11 (62–69) DOI: 10.1136/flgastro-2018-101057)
Abraham, B & Quigley, EMM 2020, , Frontline Gastroenterology, vol. 11, no. 3, pp. E1.

Antibiotics and probiotics in inflammatory bowel disease: When to use them?
Abraham, B & Quigley, EMM 2020, , Frontline Gastroenterology, vol. 11, no. 1, pp. 62-69.

The microbiome and inflammatory bowel disease
Glassner, KL, Abraham, BP & Quigley, EMM 2020, , Journal of Allergy and Clinical Immunology, vol. 145, no. 1, pp. 16-27.

Correlation of menstrual distress to severity of gastrointestinal symptoms in inflammatory bowel disease patients
Shirwaikar Thomas, A, Duran, A & Abraham, BP 2020, , Indian Journal of Gastroenterology, vol. 39, no. 5, pp. 514-520.

Nanotechnology in the treatment of inflammatory bowel disease
Giron, F, Pastó, A, Tasciotti, E & Abraham, BP 2019, , Inflammatory bowel diseases, vol. 25, no. 12, pp. 1871-1880.

The use of vedolizumab in pregnancy and breastfeeding in women with inflammatory bowel disease
Glassner, K & Abraham, BP 2019, , Practical Gastroenterology, vol. 43, no. 9, pp. 13-18.

Fecal lactoferrin testing
Abraham, BP 2018, , Gastroenterology and Hepatology, vol. 14, no. 12, pp. 713-716.

Methotrexate Is Not Superior to Placebo in Maintaining Steroid-Free Response or Remission in Ulcerative Colitis
Clinical Research Alliance of the Crohns and Colitis Foundation 2018, , Gastroenterology, vol. 155, no. 4, pp. 1098-1108.e9.

A Probiotic for Ulcerative Colitis: The Culture Wars Continue
Abraham, BP & Quigley, EMM 2018, , Digestive Diseases and Sciences, vol. 63, no. 7, pp. 1678-1680.

Lack of placental transfer of certolizumab pegol during pregnancy: Results from CRIB, a prospective, postmarketing, pharmacokinetic study
Mariette, X, Förger, F, Abraham, B, Flynn, AD, Moltó, A, Flipo, RM, Van Tubergen, A, Shaughnessy, L, Simpson, J, Teil, M, Helmer, E, Wang, M & Chakravarty, EF 2018, , Annals of the Rheumatic Diseases, vol. 77, no. 2, pp. 228-233.

Engineered biomimetic nanovesicles show intrinsic anti-inflammatory properties for the treatment of inflammatory bowel diseases
Corbo, C, Cromer, WE, Molinaro, R, Toledano Furman, NE, Hartman, KA, De Rosa, E, Boada, C, Wang, X, Zawieja, DC, Agostini, M, Salvatore, F, Abraham, BP & Tasciotti, E 2017, , Nanoscale.

Epidemiology and Risk Factors of Nonalcoholic Fatty Liver Disease among Patients with Inflammatory Bowel Disease
Glassner, K, Malaty, HM & Abraham, BP 2017, , Inflammatory bowel diseases, vol. 23, no. 6, pp. 998-1003.

Effects of Transient and Persistent Anti-drug Antibodies to Certolizumab Pegol: Longitudinal Data from a 7-Year Study in Crohn's Disease
Sandborn, WJ, Wolf, DC, Kosutic, G, Parker, G, Schreiber, S, Lee, SD, Abraham, B, Afzali, A, Arsenescu, RI, Gutierrez, A, Spearman, M, Coarse, J & Feagan, BG 2017, , Inflammatory bowel diseases, vol. 23, no. 7, pp. 1047-1056.

Polymorphisms of 5-HTT LPR and GNß3 825C>T and Response to Antidepressant Treatment in Functional Dyspepsia: A Study from the Functional Dyspepsia Treatment Trial
Saito, YA, Locke, GR, Almazar, AE, Bouras, EP, Howden, CW, Lacy, BE, Dibaise, JK, Prather, CM, Abraham, BP, El-Serag, HB, Moayyedi, P, Herrick, LM, Szarka, LA, Camilleri, M, Hamilton, FA, Schleck, CD, Tilkes, KE, Zinsmeister, AR & Talley, NJ 2017, , American Journal of Gastroenterology, vol. 112, no. 6, pp. 903-909.

Inflammatory Bowel Disease: Pathophysiology and Current Therapeutic Approaches
Abraham, BP, Ahmed, T & Ali, T 2017, . in B Greenwood-Van Meerveld (ed.), Gastrointestinal Pharmacology. vol. 239, Handbook of Experimental Pharmacology, vol. 239, Springer, pp. 115-146.